Everything below concerns GHS-R1a. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，含非天然氨基酸残基 |
| 分子量 | 711.85 g/mol | 理论值，盐形式可能略有差异 |
| 外观 | 白色至类白色粉末 | 冻干粉常见 |
| 溶解性 | 易溶于水 | 也可溶于部分极性有机溶剂 |
| 储存条件 | -20°C，干燥避光 | 长期保存通常推荐 |
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Analyses of NYTS data indicate that the decline observed between 2023 and 2024 was primarily driven by reductions among high school students. The same report noted that disparities persist, with increased in tobacco product use observed in some groups. US federal reporting has also described a longer-term pattern in which e-cigarette use among young people peaked in 2019 and declined substantially by 2024; during this period, regulatory and enforcement actions against unauthorized e-cigarette products were expanded. Data from other countries provide additional comparisons. In Great Britain, a 2024 ASH/YouGov youth survey reported that vaping among 11-17 year olds appears to have stabilized after earlier increases (ever-use 18% in 2024 compared with 20% in 2023). The same survey reported current vaping at 7.2% among 11-17 year olds (including less-than-monthly use). Additionally, UK reporting has described proposals in the Tobacco and Vapes Bill, including restrictions aimed at reducing youth uptake. Following 2024 UK survey results, the Royal College of Pediatrics and Child Health called for measures including restrictions on disposable e-cigarettes, flavors, and advertising to reduce youth uptake. In Canada, there was a trend showing 29% of young people reporting to have used e-cigarettes in 2017, increasing to 37% in 2018. In New Zealand, school survey data indicated that regular and daily vaping had declined by 2024 after peaking in 2021 and the 2024/25 the New Zealand Health Survey reported that daily smoking had reduced to below 5.0% among people aged 15–24.
10 October On the advice of Kissinger, Nixon issued secret orders to the Joint Chiefs of Staff to commence Operation Giant Lance, the sending of bombers armed with nuclear weapons toward Moscow in an effort to convince the Soviet leaders that he was not reluctant to launch a nuclear war in an effort to end the ongoing war. A squadron of 18 B-52 bombers, each carrying nuclear bombs, would be sent out on 27 October.
However, other studies suggested that perhaps expanded screening is cost effective (see ACMG report page 94-95 and articles published in Pediatrics'. Advocates are quick to point out studies such as these when trying to convince state legislatures to mandate expanded screening.
=== Vaccine development and advance market commitments === Advance Market Commitments (AMCs) aim to overcome market failure by making an advance pledge that if a vaccine for a certain condition is developed, meeting certain specifications, donors will buy a certain number of doses. Gavi seeks to design its AMCs in a way that encourages a competitive market. Gavi has been particularly successful at promoting the uptake of newer vaccines.
Sources: en.wikipedia.org
Wang, N.; He, Y.; Liu, S.; Makarcyzk, M. J.; Lei, G.; Chang, A.; Alexander, P. G.; Hao, T.; Padget, A. M.; De Pedro, N.; Menelaos, T.; Lin, H. (2022). "Engineering Osteoarthritic Cartilage Model". Science China Life Sciences. 65 (2): 309–327. doi:10.1007/s11427-021-1933-7. PMC 10077511. PMID 34109475. S2CID 235393377. Jogi, R.; Tager, M. J.; Perez, D.; Tsapekos, M. (2021). "Bovine Colostrum, Telomeres and Skin aging". Journal of Drugs in Dermatology. 20 (5): 538–545. doi:10.36849/JDD.5851. PMID 33938706. Shafa, M.; Walsh, T.; Panchalingam, K. M.; Richardson, T.; Menendez, L.; Tian, X.; Suresh Babu, S.; Dadgar, S.; Beller, J.; Yang, F.; Baghbaderani, B. A. (2019). "Long-term Stability and Differentiation Potential of Cryopreserved CGMP-compliant Human Induced Pluripotent Stem Cells". International Journal of Molecular Sciences. 21 (1): 108. doi:10.3390/ijms21010108. PMC 6982271. PMID 31877913. Samuel, P.; Tsapekos, M.; De Pedro, N.; Liu, A. G.; Casey Lippmeier, J.; Chen, S. (2022). "Ergothioneine Mitigates Telomere Shortening under Oxidative Stress Conditions". Journal of Dietary Supplements. 19 (2): 212–225. doi:10.1080/19390211.2020.1854919. PMID 33287595. S2CID 227953602. Mehkri, S.; Perez, Diego; Najarro, Pilar; Tsapekos, Menelaos; Bopanna, K. N. (July 2019). "Effect of Lutein (Lute-gen®) on Proliferation Rate and Telomere Length In Vitro and Possible Mechanism of Action". International Journal of Biology Research. 4 (3): 84–91. Phillippe, M.; Sawyer, M. R.; Edelson, P. K. (2019). "The Telomere Gestational Clock". American Journal of Obstetrics and Gynecology.
It is used as a reagent in the Bouveault aldehyde synthesis and in the Vilsmeier-Haack reaction, another useful method of forming aldehydes. It is a common solvent in the Heck reaction. It is a common catalyst used in the synthesis of acyl halides, in particular the synthesis of acyl chlorides from carboxylic acids using oxalyl or thionyl chloride. The catalytic mechanism entails reversible formation of an imidoyl chloride (also known as the 'Vilsmeier reagent'):
== Research == Baclofen is being studied for the treatment of alcoholism. Evidence as of 2019 is not conclusive enough to recommend its use for this purpose. In 2014, the French drug agency ANSM issued a three-year temporary recommendation allowing the use of baclofen in alcoholism. In 2018, baclofen received a Marketing Authorization for use in alcoholism treatment from the agency if all other treatments are not effective. It is being studied along with naltrexone and sorbitol for Charcot–Marie–Tooth disease (CMT), a hereditary disease that causes peripheral neuropathy. It is also being studied for cocaine addiction. Baclofen and other muscle relaxants are being studied for potential use for persistent hiccups. From 2014 to 2017, baclofen misuse, toxicity and use in suicide attempts among adults in the US increased. In his 2008 book, Le Dernier Verre (translated literally as The Last Glass or The End of My Addiction), French-American cardiologist Olivier Ameisen described how he treated his alcoholism with baclofen. Inspired by this book, an anonymous donor gave $750,000 to the University of Amsterdam in the Netherlands to initiate a clinical trial of high-dose baclofen, which Ameisen had called for since 2004. The researchers concluded, "In summary, the current study did not find evidence of a positive effect of either low or high doses of baclofen in AD patients. However, we cannot exclude the possibility that baclofen is an effective medication for the treatment of severe, heavy drinking AD patients not responding to or not accepting routine psychosocial interventions."
Biden was a longtime member of the Senate Committee on the Judiciary. He chaired it from 1987 to 1995 and was a ranking minority member from 1981 to 1987 and again from 1995 to 1997. As chair, Biden presided over two highly contentious U.S. Supreme Court confirmation hearings. When Robert Bork was nominated in 1988, Biden reversed his approval—given in an interview the previous year—of a hypothetical Bork nomination. Conservatives were angered, but at the hearings' close Biden was praised for his fairness, humor, and courage. Rejecting the arguments of some Bork opponents, Biden framed his objections to Bork in terms of the conflict between Bork's strong originalism and the view that the U.S. Constitution provides rights to liberty and privacy beyond those explicitly enumerated in its text. Bork's nomination was rejected in the committee by a 5–9 vote and then in the full Senate, 42–58. During Clarence Thomas's nomination hearings in 1991, Biden's questions on constitutional issues were often convoluted to the point that Thomas sometimes lost track of them, and Thomas later wrote that Biden's questions were akin to "beanballs". After the committee hearing closed, the public learned that Anita Hill had accused Thomas of making unwelcome sexual comments when they had worked together. Biden had known of some of these charges, but initially shared them only with the committee because Hill was then unwilling to testify.
They state that response to any given antipsychotic can be variable so that trials may be necessary, and that lower doses are to be preferred where possible. A number of studies have looked at levels of "compliance" or "adherence" with antipsychotic regimes and found that discontinuation (stopping taking them) by patients is associated with higher rates of relapse, including hospitalization.
Sources: en.wikipedia.org
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。
生长激素释放激素通过其专用受体起作用，而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放，但信号通路和下游效应并不相同。
研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限，长期结局尚不明确。
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。